Moderna announced that it is expanding its U.S. presence and establishing a corporate presence on the West Coast with new offices in South San Francisco, California and Seattle, Washington.
Article continues below
Moderna's Seattle location will provide technology solutions across the enterprise and Moderna Genomics will expand to South San Francisco.
Moderna also plans to hire approximately 2,000 new employees globally by the end of 2023.
Moderna's West Coast presence joins additional U.S. locations in Cambridge, Massachusetts; Norwood, Massachusetts; Atlanta, Georgia; Bethesda, Maryland; and Princeton, New Jersey.
Moderna's new office in Seattle will provide technology solutions across the enterprise and further scale the implementation of artificial intelligence (AI) and cloud-based tools across the platform by capitalizing on the region's existing technology talent.
The Company is hiring Technical Program Managers, Product Managers and Software Development Engineers.
"Moderna is investing to fully realize our ambition of embedding technology into everything we do. By building technology solutions that enable business, scientific and people-led breakthroughs, we will continue to make a positive impact on the people we serve," said Brad Miller, Chief Information Officer of Moderna.
"We are hiring rapidly in-market across key tech capabilities and are excited to grow our presence in Seattle, an area rich in highly skilled talent."
This U.S. expansion comes as Moderna is rapidly advancing its pipeline of mRNA medicines, including mRNA-4157, the Company's personalized cancer vaccine candidate, being developed in collaboration with Merck, which was recently granted Breakthrough Therapy Designation by the U.S. FDA, as well as mRNA-1345, the Company's RSV vaccine candidate, which was also recently granted Breakthrough Therapy Designation by the U.S. FDA based on positive topline data from the ConquerRSV Phase 3 pivotal efficacy trial.
Moderna currently has 48 mRNA programs in development of which 38 are in active clinical trials. Currently, the Company currently has operations in 17 countries worldwide. ■